
Opinion|Videos|January 20, 2025
Mechanism of Action of Teplizumab in Delaying Onset and Progression of Type 1
Panelists discuss how teplizumab binds to T cells and modifies their function to preserve beta cell function, potentially delaying type 1 diabetes onset in at-risk individuals by an average of 2-3 years.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Zasocitinib Tops Deucravacitinib for Skin Clearance in Phase 3 Psoriasis Trial
2
FDA Clears Wave Neuroscience MeRT System for PTSD
3
AHA, ACC Issue First Clinical Guideline for CKM Syndrome
4
AD109 Reduces OSA Severity in Phase 3 Trial of CPAP-Intolerant Adults
5






































































































































































